OTHER ASIA

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 50% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan, Hong Kong and Malaysia. Our manufacturing facility in India is our primary new product development site.

Key Countries and Territories

Hong Kong,
the Philippines,
Singapore,
Taiwan

Contribution to Group revenue

Revenue contribution - by therapeutic category

The pharmaceutical markets which Aspen defines as Other Asia (excluding China, Japan and India) grew 9% to USD45 billion for the year ended 31 December 2018

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

2

(2018: 3)^#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

USD1 million

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

24,3%

(2018: 16,5%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

Revenue	2019 R'million	2018 (CER) R'million	change %
Total	1 456	1 413	3
Regional Brands	501	531	(6)
Sterile Focus Brands	842	882	(5)
Anaesthetics Brands	675	717	(6)
Thrombosis Brands	167	165	(1)
Total Commercial Pharmaceuticals	1 343	1 413	(5)
Manufacturing – API	113	–	>100

^{Note: Commercial Pharmaceuticals revenue is disclosed by customer geography and manufacturing revenue by place of manufacture.}